The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients

被引:123
作者
Lin, Yen-Hung [1 ]
Lin, Lian-Yu [1 ]
Wu, Yen-Wen [1 ]
Chien, Kuo-Liong [1 ,4 ]
Lee, Chi-Ming [1 ]
Hsu, Ron-Bin [3 ]
Chao, Chia-Lun [1 ]
Wang, Shoei-Shen [3 ]
Hsein, Yenh-Chen [5 ]
Liao, Lin-Chu [6 ]
Ho, Yi-Lwun [1 ,2 ]
Chen, Ming-Fong [1 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Internal Med, Div Cardiol, Taipei 100, Taiwan
[2] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei 10764, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan
[4] Natl Taiwan Univ, Coll Publ Hlth, Inst Prevent Med, Taipei 10764, Taiwan
[5] Natl Taiwan Univ Hosp, Dept Clin Pathol, Yun Lin Branch, Yunlin, Taiwan
[6] Natl Taiwan Univ Hosp, Dept Pharm, Yun Lin Branch, Yunlin, Taiwan
关键词
Galectin-3; Extracellular matrix; Heart failure; Collagen; Matrix metalloproteinase; AMINO-TERMINAL PROPEPTIDE; CORONARY-ARTERY-DISEASE; III PROCOLLAGEN; CIRCULATING LEVELS; FIBROSIS; CARDIOMYOPATHY; MACROPHAGES; DYSFUNCTION; BIOMARKERS; MANAGEMENT;
D O I
10.1016/j.cca.2009.09.001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: A growing body of evidence links macrophage activation and fibrosis to the pathogenesis of heart failure (HF). Galectin-3 is one of the most likely mediators between macrophage activation and myocardial fibrosis. However, the exact relationship is unknown in humans. We assessed the impact of galectin-3 on serum markers of cardiac extracellular matrix (ECM) turnover in HF patients. Methods: Patients with HF manifestations and a left ventricular ejection fraction (LVEF) <= 50% were enrolled in this study. Gender, age, medications. serum biochemical data, and outcomes of heart failure were recorded. Serum galectin-3, extracellular matrix including type I and III aminoterminal propeptide of procollagen (PINP and PIIINP), matrix metalloproteinase-2 (MMP-2), and tissue inhibitor of metalloproteinase-1 (TIMP-1) were analyzed. Results: A total of 106 (83 males and 23 females) patients were enrolled. The age was 61 +/- 16 y and LVEF was 35 +/- 9%. Their mean NYHA functional class was 2.2. Log galectin-3 was significantly correlated with log PIIINP (p = 0.006), log TIMP-1 (p = 0.025), log MMP-2 (p = 0.016), and NYHA functional class (p = 0.034); but not age, sex or LVEF. After adjusting for age, sex, smoking status and LVEF, the relationship between galectin-3 and ECM turnover biomarkers (including PIIINP, TIMP, and MMP-2) remained significant. After adjusting for age, sex. smoking status and NYHA functional class, the relationship between galectin-3 and PIIINP or MMP-2 remained significant. Conclusions: Galectin-3 is significantly correlated with serum markers of cardiac ECM turnover in HF patients. This implies a relationship between macrophage activation and ECM turnover in patients with HF. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:96 / 99
页数:4
相关论文
共 27 条
[1]   Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure [J].
Cicoira, M ;
Rossi, A ;
Bonapace, S ;
Zanolla, L ;
Golia, G ;
Franceschini, L ;
Caruso, B ;
Marino, PN ;
Zardini, P .
JOURNAL OF CARDIAC FAILURE, 2004, 10 (05) :403-411
[2]  
Devaux B, 1997, EUR HEART J, V18, P470
[3]   Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure [J].
George, J ;
Patal, S ;
Wexler, D ;
Roth, A ;
Sheps, D ;
Keren, G .
AMERICAN HEART JOURNAL, 2005, 150 (03) :484-487
[4]   Extracellular matrix profiles in the progression to heart failure - European young physiologists symposium keynote lecture-Bratislava 2007 [J].
Graham, H. K. ;
Horn, M. ;
Trafford, A. W. .
ACTA PHYSIOLOGICA, 2008, 194 (01) :3-21
[5]   Galectin-3 regulates myofibroblast activation and hepatic fibrosis [J].
Henderson, NC ;
Mackinnon, AC ;
Farnworth, SL ;
Poirier, F ;
Russo, FP ;
Iredale, JP ;
Haslett, C ;
Simpson, KJ ;
Sethi, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (13) :5060-5065
[6]   Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis [J].
Henderson, Neil C. ;
Mackinnon, Alison C. ;
Farnworth, Sarah L. ;
Kipari, Tiina ;
Haslett, Christopher ;
Iredale, John P. ;
Liu, Fu-Tong ;
Hughes, Jeremy ;
Sethi, Tariq .
AMERICAN JOURNAL OF PATHOLOGY, 2008, 172 (02) :288-298
[7]   Improved cost-effectiveness for management of chronic heart failure by combined home-based intervention with clinical nursing specialists [J].
Ho, Yi-Lwun ;
Hsu, Tse-Pin ;
Chen, Chiou-Ping ;
Lee, Chu-Yuan ;
Lin, Yen-Hung ;
Hsu, Ron-Bin ;
Wu, Yen-Wen ;
Chou, Nai-Kuan ;
Lee, Chi-Ming ;
Wang, Shoei-Shen ;
Ting, Hsiu-Tzu ;
Chen, Ming-Fong .
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2007, 106 (04) :313-319
[8]   ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult - Summary article [J].
Hunt, SA ;
Abraham, WT ;
Chin, MH ;
Feldman, AM ;
Francis, GS ;
Ganiats, TG ;
Jessup, M ;
Konstam, MA ;
Mancini, DM ;
Michl, K ;
Oates, JA ;
Rahko, PS ;
Silver, MA ;
Stevenson, LW ;
Yancy, CW .
CIRCULATION, 2005, 112 (12) :1825-1852
[9]   Association of amino-terminal propeptide of type III procollagen and acute myocardial rejection in male patients receiving heart transplantation [J].
Lin, Yen-Hung ;
Liu, Chung-Pin ;
Hsu, Ron-Bin ;
Lee, Chi-Ming ;
Wang, Shoei-Shen ;
Kao, Hsien-Li ;
Chao, Chia-Lun ;
Shiau, Yu-Chien ;
Hung, Chi-Sheng ;
Liao, Lin-Chu ;
Ho, Yi-Lwun .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2007, 45 (08) :1004-1008
[10]   The relation of amino-terminal propeptide of type III procollagen and severity of coronary artery disease in patients without myocardial infarction or hibernation [J].
Lin, Yen-Hung ;
Ho, Yi-Lwun ;
Wang, Tzung-Dau ;
Liu, Chung-Pin ;
Kao, Hsien-Li ;
Chao, Chia-Lun ;
Chien, Kuo-Liong ;
Hung, Chi-Sheng ;
Wu, Vin-Cent ;
Tsai, I-Jung ;
Yen, Ruoh-Fang ;
Shiau, Yu-Chien ;
Chen, Wen-Jone .
CLINICAL BIOCHEMISTRY, 2006, 39 (09) :861-866